Eli Lilly: obesity-drug scale is now a manufacturing and cash-conversion test

Eli Lilly reported FY2025 revenue of $65.2 billion and 2026 Q1 revenue of $19.8 billion. The thesis depends on tirzepatide demand, manufacturing capacity, pipeline reinvestment and cash conversion.

ClaimFilingCashCustomerConviction

Slide mode Article mode

Eli Lilly reported FY2025 revenue of $65.2 billion and 2026 Q1 revenue of $19.8 billion. The thesis depends on tirzepatide demand, manufacturing capacity, pipeline reinvestment and cash conversion.

References

Sources used in this report

SEC datasetSEC company tickers exchange datasetRetrieved 2026-05-19 · Issuer identity, ticker, exchange and CIK SEC APISEC submissions APIRetrieved 2026-05-19 · Filing chronology and company identity SEC XBRL APISEC companyfacts APIRetrieved 2026-05-19 · Financial statement cross-checks Annual reportFY2025 Form 10-K filed 2026-02-122026 · Annual business, risk and financial baseline Quarterly reportForm 10-Q filed 2026-04-302026 · Latest interim financials and balance sheet Form 8-KForm 8-K filed 2026-04-302026 · Recent filing chronology and update context Company earnings releaseEarnings release exhibit2026 · Company-reported operating update filed with the SEC Proxy statementDEF 14A filed 2026-03-202026 · Governance and incentive framing